New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Finds - The New York Times

With a 6-4 vote, the group of independent advisers to the agency narrowly concluded that results from another clinical trial are needed to assess whether the therapy, called AMX0035, can help patients.

Their company financed the bulk of the study, but the A.L.S. Association, a patient advocacy group, contributed $2.2 million, using money raised through the 2014 Ice Bucket Challenge. Amylyx agreed t… [+1831 chars]

full article...